- Company
- Exkivity applies for reimbursement
- by Eo, Yun-Ho Mar 7, 2023 05:38am
- Exkivity, an anti-cancer drug targeting EGFR exon 20 insertion mutation, is aiming for insurance coverage. Takeda Korea recently submitted a reimbursement application for Exkivity, a treatment for non-small cell lung cancer (NSCLC) with an EGFR exon 20 insertion mutation. This drug targets the same biomarker as Janssen's Rybrevant but differs
- Company
- Boryung officially launches Zepzelca
- by Kim, Jin-Gu Mar 6, 2023 05:56am
- Boryung announced on the 28th that it has officially launched Zepzelca, a new small-cell lung cancer drug, in Korea. Zepzelca is a new anticancer drug developed by PharmaMar S.A. It is used for metastatic small-cell lung cancer that has failed first-line platinum-based chemotherapy. Zepzelca is a new drug with a mechanism that simultaneously
- Company
- ‘No regrets...happy to have served at Daiichi Sankyo Korea'
- by Eo, Yun-Ho Mar 6, 2023 05:56am
- “I have no regrets. Although I have no specific plans set for the future, I would like to say it was a great honor to have served over 30 years at Daiichi Sankyo, and will cherish the memory forever.” Dae Jung Kim (63), President of Daiichi Sankyo Korea and the longest-serving multinational pharmaceutical company CEO in Korea, is leavin
- Company
- JAK inhibitor market jumped 2.4 times in 3 years
- by Kim, Jin-Gu Mar 3, 2023 05:57am
- The market for Janus kinase (JAK) inhibitors, an oral autoimmune disease treatment drug, has expanded 2.4 times over the past three years. In addition to Xeljanz, which was leading the market, new products such as Olumiant and Rinvoq were added, and each product actively expanded its indications. Competition between major products is also ge
- Company
- Obesity mkt grows larger than ever...Saxenda leads mkt
- by Chon, Seung-Hyun Mar 3, 2023 05:57am
- The domestic obesity treatment market grew to record an all-time high last year. Saxenda maintained its unrivaled lead for 4 consecutive years and left its competitor Qsymia far behind. According to the market research institution IQVIA on the 2nd, the obesity treatment market grew 22.4% YoY to reach KRW 175.7 billion last year. The obesity
- Company
- Organizations and people change
- by Eo, Yun-Ho Mar 3, 2023 05:57am
- The Korean branch of Gilead is facing the most significant transformation since its inception in Korea. Various changes such as the establishment of a new business unit are expected along with changes in the composition of the workforce, such as the resignation of executive director Jeong Yeon-shin, a key member of Gilead Sciences Korea al
- Company
- MFDS approves LG Chem’s P3T for new gout drug
- by Hwang, Jin-joon Mar 3, 2023 05:56am
- On the 28th, LG Chem announced that its global Phase III clinical trial protocol (EURELIA 2 Study) for ‘tigulixostat’ was approved by the Ministry of Food and Drug Safety. Tigulixostat is a new gout drug candidate being developed by LG Chem. The Phase III trial will enroll 2,600 gout patients with hyperuricemia around the globe. LG
- Company
- Corona drug competition system is imminent
- by Jung, Sae-Im Mar 3, 2023 05:55am
- As the COVID-19 pandemic shows signs of ending this year, pharmaceutical companies supplying related medicines are in the midst of preparing marketing and sales personnel to prepare for the end of the pandemic. According to the pharmaceutical industry on the 24th, Pfizer Korea is currently hiring large-scale new sales staff. The number of
- Company
- Sky Zoster ranked first in sales of shingles vaccine last yr
- by Kim, Jin-Gu Mar 2, 2023 05:53am
- SK Bioscience announced on the 28th, citing IMS data, a global market research institute, that its self-developed shingles vaccine Sky Zoster achieved the top share in sales in the domestic market last year. According to SK Bioscience, Sky Zoster's domestic market share last year reached 54% based on sales volume. Quarterly by quarter, 51
- Company
- Samsung Bioepis fiercely chases Celltrion in biosimilar mkt
- by Kim, Jin-Gu Mar 2, 2023 05:53am
- Samsung Bioepis has been rapidly chasing Celltrion in the domestic biosimilar business and expanding sales in the market. As of last year, domestic biosimilar sales of Samsung Bioepis and Celltrion were KRW 42.5 billion and KRW 69 billion, respectively. Samsung Bioepis’s sales more than tripled in one year, greatly narrowing the gap with
